Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy.

ABSTRACT:

Purpose

Androgen-deprivation therapy (ADT) for prostate cancer is associated with bone loss and osteoporotic fractures. Our objective was to examine changes in bone density and turnover with sustained, discontinued, or delayed oral bisphosphonate therapy in men receiving ADT.

Patients and methods

A total of 112 men with nonmetastatic prostate cancer receiving ADT were randomly assigned to alendronate 70 mg once weekly or placebo in a double-blind, partial-crossover trial with a second random assignment at year 2 for those who initially received active therapy. Outcomes included bone mineral density and bone turnover markers.

Results

Men initially randomly assigned to alendronate and randomly reassigned at year 2 to continue had additional bone density gains at the spi

SUBMITTER: Greenspan SL 

PROVIDER: S-EPMC2653114 | biostudies-literature | 2008 Sep

REPOSITORIES: biostudies-literature